



***Express Mail No. EV 531 696 338 US***

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: van den Berg *et al.*

Confirmation No.: 5284

Serial No.: 10/007,275

Art Unit: 1642

Filed: October 26, 2001

Examiner: Christopher H. Yaen

For: METHOD FOR INHIBITING CELL  
FUNCTIONING FOR USE IN ANTI-  
INFLAMMATORY AND ANTI-TUMOR  
THERAPIES

Attorney Docket No: 080743-235001

**AMENDMENT FEE TRANSMITTAL SHEET**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be **\$0.00**.

Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: December 2, 2004

Margaret B. Brivanlou  
Margaret B. Brivanlou

40,922  
(Reg. No.)

By: William J. Thomann  
William J. Thomann

40,203  
(Reg. No.)

JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 901-9028



12-03-04

IFW 1642\$

Express Mail No.: EV 531 696 338 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: van den Berg *et al.*

Confirmation No.: 5284

Serial No.: 10/007,275

Group Art Unit: 1642

Filed: October 26, 2001

Examiner: Christopher H. Yaen

For: METHOD FOR INHIBITING CELL  
FUNCTIONING FOR USE IN ANTI-  
INFLAMMATORY AND ANTI-TUMOR  
THERAPIES

Attorney Docket No.: 080743-235001

REPLY UNDER 37 C.F.R. § 1.111 WITH AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the outstanding Office Action, dated June 2, 2004, please enter the following amendments and consider the remarks made below in connection with the above-identified application. Applicants submit concurrently herewith (a) a Petition under 37 C.F.R. § 1.36(a) for an Extension of Time for Response for a period of three months from September 2, 2004 up to December 2, 2004, accompanied by the required fee; (b) an Amendment Fee Transmittal Sheet; and (c) a Statement of Permanence and Availability of Deposited Hybridomas.

**Amendments to the Specification** begin on page 2 of this paper

**Amendments to the Claims** begin on page 3 of this paper.

**Remarks** begin on page 5 of this paper.